Subscribe To
CRSP / CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?
![CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?](https://cdn.snapi.dev/images/v1/1/k/default267-2135208.jpg)
CRSP News
![Why CRISPR Therapeutics Stock Charged Northward This Week Why CRISPR Therapeutics Stock Charged Northward This Week](https://cdn.snapi.dev/images/v1/j/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7536652fbiotechjpgopresizew400h400-2139076.jpg)
By The Motley Fool
November 3, 2023
Why CRISPR Therapeutics Stock Charged Northward This Week
Gene therapy has been on a roller-coaster ride since the first patient was treated 33 years ago. This slow-motion story took another turn this week af more_horizontal
![CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for Investors CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for Investors](https://cdn.snapi.dev/images/v1/n/w/default34-2136806.jpg)
By Zacks Investment Research
November 2, 2023
CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for Investors
CRISPR Therapeutics AG (CRSP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recentl more_horizontal
![CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains? CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?](https://cdn.snapi.dev/images/v1/1/k/default267-2135208.jpg)
By Zacks Investment Research
November 2, 2023
CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?
CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings est more_horizontal
![Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients](https://cdn.snapi.dev/images/v1/3/f/3fvfre3-2131782.jpg)
By NYTimes
October 31, 2023
Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients
The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-ed more_horizontal
![FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia](https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7465732fdoctor-with-patient-talkingjpgopresizew400h400-2055522-2131440.jpg)
By Barrons
October 31, 2023
FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia
Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease. more_horizontal
![CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision](https://cdn.snapi.dev/images/v1/4/4/crispr-theraputics-crsp-stock-1600-2131316.jpg)
By InvestorPlace
October 31, 2023
CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision
Among the more prominent gene-editing stocks on the market, investors in this space pay particularly close attention to CRISPR Therapeutics (NASDAQ: C more_horizontal
![CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy](https://cdn.snapi.dev/images/v1/y/f/crispr-theraputics-crsp-stock-1600-2126475.jpg)
By InvestorPlace
October 27, 2023
CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy
Shares of genetic engineering specialist CRISPR Therapeutics (NASDAQ: CRSP ) moved up modestly on Friday as stakeholders await a final regulatory deci more_horizontal
![2 Fantastic Growth Stocks to Buy Hand Over Fist 2 Fantastic Growth Stocks to Buy Hand Over Fist](https://cdn.snapi.dev/images/v1/5/3/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7521922finvestor-smiling-phone-at-homejpgopresizew400h400-2121962.jpg)
By The Motley Fool
October 26, 2023
2 Fantastic Growth Stocks to Buy Hand Over Fist
CRISPR Therapeutics may soon launch its first approved product. The economic environment has weighed on Etsy, but recent trends show growth may be rea more_horizontal